Lung Cancer News

An analysis of the online conversations of more than 1,000 health care professionals worldwide through May revealed positive reactions to the approval of three key treatment options for patients with cancer.

CHICAGO — An algorithm-based default referrals system led to a fourfold increase in specialty palliative care use when implemented in a large community oncology network, results of a randomized study presented at ASCO Annual Meeting showed.

CHICAGO — A stepped palliative care model delivering early care at key points for patients with advanced cancer resulted in fewer visits while still maintaining quality-of-life benefits, results from a randomized study showed.

CHICAGO — Individuals with KRAS-mutant lung cancer treated with adagrasib experienced significantly prolonged PFS compared with docetaxel, randomized study results presented at ASCO Annual Meeting showed.

CHICAGO — The addition of subcutaneous amivantamab to lazertinib demonstrated noninferior pharmacokinetics and objective response rate compared with intravenous amivantamab, results from a phase 3 study showed.

SAN DIEGO — Fewer patients with lung nodules had complications during a navigational bronchoscopy procedure vs. a CT-guided biopsy, according to research presented at the American Thoracic Society International Conference.

CHICAGO — Durvalumab conferred significant survival benefits in patients with limited-stage small-cell lung cancer following standard-of-care treatment in a randomized phase 3 trial, according to findings presented at ASCO Annual Meeting.

CHICAGO — Healio once again welcomed the excitement of the Disruptive Innovator Awards, working with new partners and celebrating nine distinct areas of progress in oncology and hematology.

When Robert A. Winn, MD, learned he’d receive the Allen Lichter Visionary Leader Award at this year’s ASCO Annual Meeting, he reacted in the form of a question: “What just happened?”

CHICAGO — Osimertinib following chemoradiotherapy drastically improved PFS compared with placebo in patients with advanced EGFR-mutant non-small cell lung cancer in a randomized phase 3 trial.